WallStSmart

Merck & Company Inc (MRK)vsTriSalus Life Sciences Inc. (TLSI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 146432% more annual revenue ($65.77B vs $44.88M). MRK leads profitability with a 13.6% profit margin vs -60.9%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

TLSI

Avoid

16

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -13.69
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-42.4%)

Margin of Safety

-42.4%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for TLSI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

TLSI0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TLSI4 concerns · Avg: 3.3/10
Price/BookValuation
15.7x4/10

Trading at 15.7x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$223.56M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-496.2%2/10

ROE of -496.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : TLSI

TLSI has a balanced fundamental profile.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : TLSI

The primary concerns for TLSI are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.69 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while TLSI is a turnaround play — different risk/reward profiles.

TLSI carries more volatility with a beta of 0.49 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

TriSalus Life Sciences Inc.

HEALTHCARE · MEDICAL DEVICES · USA

TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary localized drug delivery systems. By enhancing the effectiveness of immuno-oncology agents and overcoming distribution challenges within tumor microenvironments, TriSalus is dedicated to improving therapeutic outcomes for cancer patients. With a promising pipeline of clinical programs, the company aims to meet the urgent demand for advanced cancer therapies. Positioned strategically within the dynamic oncology landscape, TriSalus is poised for significant impact as it seeks to expand access to its groundbreaking treatments.

Want to dig deeper into these stocks?